FDA Review of Investigational Use of COVID-19 Convalescent Plasma
Salim El Haddad, Nicole Verdun(Center for Biologics Evaluation and Research), Carlos H. Villa(Center for Biologics Evaluation and Research), Charles Maplethorpe, Laurence Landow, Victor C. Baum, Addisalem Taye Makuria, Emily K. Storch, W. E. PAUL, Anne F. Eder(Center for Biologics Evaluation and Research)
Unknown
January 1, 2020
Cited by 6
Related Papers
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19
|New England Journal of Medicine|2021|553
Early safety indicators of COVID-19 convalescent plasma in 5000 patients
|Journal of Clinical Investigation|2020|485
Safety Update
|Mayo Clinic Proceedings|2020|432
Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2024|257
FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia
|Clinical Cancer Research|2015|165